{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T06:22:21Z","timestamp":1771395741942,"version":"3.50.1"},"reference-count":65,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.jaad.2025.10.055","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T06:45:14Z","timestamp":1760683514000},"page":"895-902","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Biologic therapies for dermatologic emergencies: A comprehensive review"],"prefix":"10.1016","volume":"94","author":[{"given":"Nina","family":"Modanlo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyle","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael O.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda","family":"Truong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jaad.2025.10.055_bib1","doi-asserted-by":"crossref","DOI":"10.1111\/dth.13687","article-title":"Considerations for safety in the use of systemic medications for psoriasis and atopic dermatitis during the COVID-19 pandemic","volume":"33","author":"Ricardo","year":"2020","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jaad.2025.10.055_bib2","doi-asserted-by":"crossref","unstructured":"Awad A, Goh MS, Trubiano JA. Drug reaction with eosinophilia and systemic symptoms: a systematic review. J Allergy Clin Immunol Pract. 11(6), 1856-1868. https:\/\/doi.org\/10.1016\/j.jaip.2023.02.035","DOI":"10.1016\/j.jaip.2023.02.035"},{"issue":"6","key":"10.1016\/j.jaad.2025.10.055_bib3","first-page":"31","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome","volume":"6","author":"Choudhary","year":"2013","journal-title":"J Clin Aesthet Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2025.10.055_bib4","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1001\/jamadermatol.2020.0048","article-title":"Evaluation of cyclosporine for the treatment of DRESS syndrome","volume":"156","author":"Nguyen","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2025.10.055_bib5","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s40629-022-00224-7","article-title":"Treatment with IL5-\/IL-5 receptor antagonists in drug reaction with eosinophilia and systemic symptoms (DRESS)","volume":"32","author":"Gschwend","year":"2023","journal-title":"Allergo J Int"},{"issue":"1","key":"10.1016\/j.jaad.2025.10.055_bib6","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.jaip.2020.09.039","article-title":"Benralizumab for severe DRESS in two COVID-19 patients","volume":"9","author":"Schmid-Grendelmeier","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"10.1016\/j.jaad.2025.10.055_bib7","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1159\/000519471","article-title":"Successful treatment of imatinib-induced DRESS syndrome using reslizumab without cessation of imatinib: a case report","volume":"14","author":"Park","year":"2021","journal-title":"Case Rep Oncol"},{"issue":"6","key":"10.1016\/j.jaad.2025.10.055_bib8","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1001\/jamadermatol.2025.0441","article-title":"IL-5 inhibitor treatment in drug reaction with eosinophilia and systemic symptoms","volume":"161","author":"Hijaz","year":"2025","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2025.10.055_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1134178","article-title":"Novel targeted inhibition of the IL-5 axis for drug reaction with eosinophilia and systemic symptoms syndrome","volume":"14","author":"Rubin","year":"2023","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.jaad.2025.10.055_bib10","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s40265-024-02037-0","article-title":"Anti-IL-5 pathway agents in eosinophilic-associated disorders across the lifespan","volume":"84","author":"Lombardi","year":"2024","journal-title":"Drugs"},{"issue":"12","key":"10.1016\/j.jaad.2025.10.055_bib11","doi-asserted-by":"crossref","first-page":"3789","DOI":"10.1016\/j.jaip.2023.08.028","article-title":"Dupilumab to treat drug reaction with eosinophilia and systemic symptoms: a case series","volume":"11","author":"Dubin","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaad.2025.10.055_bib12","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jdcr.2024.03.020","article-title":"Treatment of prolonged drug reaction with eosinophilia and systemic symptoms syndrome with dupilumab using a molecularly-guided approach","volume":"48","author":"Valido","year":"2024","journal-title":"JAAD Case Rep"},{"issue":"6","key":"10.1016\/j.jaad.2025.10.055_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.anai.2024.08.527","article-title":"A rare case of severe exacerbation of hypereosinophilic syndrome with dupilumab","volume":"133","author":"Ashraf","year":"2024","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"3","key":"10.1016\/j.jaad.2025.10.055_bib14","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1111\/cts.13201","article-title":"Efficacy of add-on therapy with intravenous immunoglobulin in steroid hyporesponsive DRESS syndrome","volume":"15","author":"Sim","year":"2022","journal-title":"Clin Transl Sci"},{"issue":"4","key":"10.1016\/j.jaad.2025.10.055_bib15","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/j.jaip.2017.10.016","article-title":"Successful intravenous immunoglobulin treatment in pediatric severe DRESS syndrome","volume":"6","author":"Marcus","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"4","key":"10.1016\/j.jaad.2025.10.055_bib16","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1001\/archderm.148.4.dlt120002-c","article-title":"Poor benefit\/risk balance of intravenous immunoglobulins in DRESS","volume":"148","author":"Joly","year":"2012","journal-title":"Arch Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2025.10.055_bib17","first-page":"195","article-title":"A rare pediatric case of allopurinol-induced drug reaction with eosinophilia and systemic symptoms (DRESS) successfully treated with intravenous immunoglobulins","volume":"29","author":"Rotulo","year":"2024","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.jaad.2025.10.055_bib18","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.jaad.2020.03.081","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS) in the pediatric population: a systematic review of the literature","volume":"83","author":"Kim","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2025.10.055_bib19","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/j.jid.2017.01.031","article-title":"The epidemiology of Stevens-Johnson syndrome and toxic epidermal necrolysis in the UK","volume":"137","author":"Frey","year":"2017","journal-title":"J Invest Dermatol"},{"issue":"7","key":"10.1016\/j.jaad.2025.10.055_bib20","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/j.jid.2016.03.023","article-title":"Morbidity and mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis in United States adults","volume":"136","author":"Hsu","year":"2016","journal-title":"J Invest Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2025.10.055_bib21","doi-asserted-by":"crossref","first-page":"203","DOI":"10.3904\/kjim.2012.27.2.203","article-title":"Causes and treatment outcomes of Stevens-Johnson syndrome and toxic epidermal necrolysis in 82 adult patients","volume":"27","author":"Kim","year":"2012","journal-title":"Korean J Intern Med"},{"issue":"5","key":"10.1016\/j.jaad.2025.10.055_bib22","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/jid.2012.510","article-title":"Comprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"133","author":"Sekula","year":"2013","journal-title":"J Invest Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2025.10.055_bib23","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1172\/JCI93349","article-title":"Randomized, controlled trial of TNF-\u03b1 antagonist in CTL-mediated severe cutaneous adverse reactions","volume":"128","author":"Wang","year":"2018","journal-title":"J Clin Invest"},{"issue":"8","key":"10.1016\/j.jaad.2025.10.055_bib24","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1001\/jamadermatol.2019.3731","article-title":"Use of etanercept in a series of pediatric patients with Stevens-Johnson syndrome-toxic epidermal necrolysis spectrum disease","volume":"156","author":"Eliades","year":"2020","journal-title":"JAMA Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2025.10.055_bib25","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.anai.2022.05.009","article-title":"Etanercept treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"129","author":"Tian","year":"2022","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"7","key":"10.1016\/j.jaad.2025.10.055_bib26","first-page":"758","article-title":"Treatment of toxic epidermal necrolysis with etanercept in a pediatric patient","volume":"26","author":"Zander","year":"2021","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.jaad.2025.10.055_bib27","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/j.jaip.2022.01.038","article-title":"Evaluation of combination therapy with etanercept and systemic corticosteroids for Stevens-Johnson syndrome and toxic epidermal necrolysis: a multicenter observational study","volume":"10","author":"Zhang","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaad.2025.10.055_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1421684","article-title":"Tumor necrosis factor inhibitors enhance corticosteroid therapy for Stevens-Johnson syndrome and toxic epidermal necrolysis linked to immune checkpoint inhibitors: a prospective study","volume":"15","author":"He","year":"2024","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.jaad.2025.10.055_bib29","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.jaad.2014.04.044","article-title":"Etanercept therapy for toxic epidermal necrolysis","volume":"71","author":"Paradisi","year":"2014","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2025.10.055_bib30","article-title":"Systemic interventions for treatment of Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS\/TEN overlap syndrome","volume":"3","author":"Jacobsen","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"issue":"9","key":"10.1016\/j.jaad.2025.10.055_bib31","doi-asserted-by":"crossref","first-page":"921","DOI":"10.3390\/medicina57090921","article-title":"Recent updates in the treatment of erythema multiforme","volume":"57","author":"Soares","year":"2021","journal-title":"Medicina (Kaunas)"},{"issue":"2","key":"10.1016\/j.jaad.2025.10.055_bib32","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jdcr.2016.11.009","article-title":"Treatment of recurrent erythema multiforme with adalimumab as monotherapy","volume":"3","author":"Baillis","year":"2017","journal-title":"JAAD Case Rep"},{"issue":"3","key":"10.1016\/j.jaad.2025.10.055_bib33","doi-asserted-by":"crossref","first-page":"P95","DOI":"10.1016\/j.jaad.2003.10.306","article-title":"Severe erythema multiforme responding to high dose intravenous immunoglobulin therapy1","volume":"50","author":"Singh","year":"2004","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"10.1016\/j.jaad.2025.10.055_bib34","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1111\/jdv.13313","article-title":"Rituximab, a new treatment for difficult-to-treat chronic erythema multiforme major? Five cases","volume":"30","author":"Hirsch","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2025.10.055_bib35","doi-asserted-by":"crossref","unstructured":"Tonkin R, Ladha M, Johnson N, et al. Reactive infectious mucocutaneous eruption - repeat etanercept after intravenous immunoglobulin: a case report. SAGE Open Med Case Rep. 2022:2050313X221117887. https:\/\/doi.org\/10.1177\/2050313X221117887","DOI":"10.1177\/2050313X221117887"},{"issue":"2","key":"10.1016\/j.jaad.2025.10.055_bib36","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1001\/jamadermatol.2020.5166","article-title":"Evaluation of etanercept for treatment of reactive infectious mucocutaneous eruption","volume":"157","author":"Miller","year":"2021","journal-title":"JAMA Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2025.10.055_bib37","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1001\/archderm.139.1.33","article-title":"Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression","volume":"139","author":"Bachot","year":"2003","journal-title":"Arch Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2025.10.055_bib38","doi-asserted-by":"crossref","first-page":"506","DOI":"10.4103\/0378-6323.113080","article-title":"Low dose intravenous immunoglobulins and steroids in toxic epidermal necrolysis: a prospective comparative open-labelled study of 36 cases","volume":"79","author":"Jagadeesan","year":"2013","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"6","key":"10.1016\/j.jaad.2025.10.055_bib39","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1001\/jamadermatol.2016.5668","article-title":"Systemic immunomodulating therapies for Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis","volume":"153","author":"Zimmermann","year":"2017","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2025.10.055_bib40","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1146\/annurev-pathol-012615-044313","article-title":"Mechanisms of disease: pemphigus and bullous pemphigoid","volume":"11","author":"Hammers","year":"2016","journal-title":"Annu Rev Pathol"},{"issue":"2","key":"10.1016\/j.jaad.2025.10.055_bib41","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0190-9622(82)70111-2","article-title":"Death in pemphigus","volume":"7","author":"Ahmed","year":"1982","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"10.1016\/j.jaad.2025.10.055_bib42","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.3390\/medicina57101080","article-title":"An updated review of pemphigus diseases","volume":"57","author":"Malik","year":"2021","journal-title":"Medicina (Kaunas)"},{"issue":"10083","key":"10.1016\/j.jaad.2025.10.055_bib43","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/S0140-6736(17)30070-3","article-title":"First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial","volume":"389","author":"Joly","year":"2017","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.jaad.2025.10.055_bib44","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1111\/jdv.16752","article-title":"Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the European academy of dermatology and venereology (EADV)","volume":"34","author":"Joly","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"10.1016\/j.jaad.2025.10.055_bib45","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jaad.2018.02.021","article-title":"Diagnosis and management of pemphigus: recommendations of an international panel of experts","volume":"82","author":"Murrell","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2025.10.055_bib46","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.jdin.2021.10.002","article-title":"Efficacy of rituximab in pediatric pemphigus: a literature review","volume":"6","author":"Patel","year":"2021","journal-title":"JAAD Int"},{"issue":"4","key":"10.1016\/j.jaad.2025.10.055_bib47","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.jaad.2008.09.052","article-title":"A randomized double-blind trial of intravenous immunoglobulin for pemphigus","volume":"60","author":"Amagai","year":"2009","journal-title":"J Am Acad Dermatol"},{"issue":"17","key":"10.1016\/j.jaad.2025.10.055_bib48","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1056\/NEJMoa062930","article-title":"Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin","volume":"355","author":"Ahmed","year":"2006","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jaad.2025.10.055_bib49","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/bjd.20782","article-title":"Treatment of pemphigus vulgaris and foliaceus with efgartigimod, a neonatal Fc receptor inhibitor: a phase II multicentre, open-label feasibility trial","volume":"186","author":"Goebeler","year":"2022","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2025.10.055_bib51","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.jaad.2023.09.080","article-title":"Generalized pustular psoriasis: a consensus statement from the National Psoriasis Foundation","volume":"90","author":"Armstrong","year":"2024","journal-title":"J Am Acad Dermatol"},{"issue":"Suppl 1","key":"10.1016\/j.jaad.2025.10.055_bib52","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s40257-021-00655-y","article-title":"Pathophysiology of generalized pustular psoriasis","volume":"23","author":"Marrakchi","year":"2022","journal-title":"Am J Clin Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2025.10.055_bib53","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/ijd.12070","article-title":"Clinical profile, morbidity, and outcome of adult-onset generalized pustular psoriasis: analysis of 102 cases seen in a tertiary hospital in Johor, Malaysia","volume":"53","author":"Choon","year":"2014","journal-title":"Int J Dermatol"},{"issue":"12","key":"10.1016\/j.jaad.2025.10.055_bib54","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/j.1365-2133.1968.tb11947.x","article-title":"Generalized pustular psoriasis. A clinical and epidemiological study of 104 cases","volume":"80","author":"Baker","year":"1968","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2025.10.055_bib55","first-page":"669","article-title":"Generalized pustular psoriasis (Zumbusch): a French epidemiological survey","volume":"16","author":"Augey","year":"2006","journal-title":"Eur J Dermatol"},{"issue":"10","key":"10.1016\/j.jaad.2025.10.055_bib56","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1111\/jdv.14949","article-title":"Generalized pustular psoriasis: a review and update on treatment","volume":"32","author":"Hoegler","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"26","key":"10.1016\/j.jaad.2025.10.055_bib57","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1056\/NEJMoa2111563","article-title":"Trial of spesolimab for generalized pustular psoriasis","volume":"385","author":"Bachelez","year":"2021","journal-title":"N Eng J Med"},{"key":"10.1016\/j.jaad.2025.10.055_bib58","doi-asserted-by":"crossref","first-page":"8199","DOI":"10.2147\/JIR.S485077","article-title":"Successful Treatment of pediatric generalized pustular psoriasis (GPP) with spesolimab: 5 case reports and evaluations of circulating IL-36 levels","volume":"17","author":"Chen","year":"2024","journal-title":"J Inflamm Res"},{"issue":"4","key":"10.1016\/j.jaad.2025.10.055_bib59","doi-asserted-by":"crossref","first-page":"184","DOI":"10.2310\/7750.2008.07036","article-title":"Long-term management of generalized pustular psoriasis with infliximab: case series","volume":"12","author":"Routhouska","year":"2008","journal-title":"J Cutan Med Surg"},{"issue":"12","key":"10.1016\/j.jaad.2025.10.055_bib60","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1111\/1346-8138.14664","article-title":"Adalimumab treatment in Japanese patients with generalized pustular psoriasis: results of an open-label phase 3 study","volume":"45","author":"Morita","year":"2018","journal-title":"J Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2025.10.055_bib61","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1159\/000117706","article-title":"Etanercept at different dosages in the treatment of generalized pustular psoriasis: a case series","volume":"216","author":"Esposito","year":"2008","journal-title":"Dermatology"},{"issue":"6","key":"10.1016\/j.jaad.2025.10.055_bib62","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1080\/09546634.2022.2089327","article-title":"Efficacy of adalimumab in pediatric generalized pustular psoriasis: case series and literature review","volume":"33","author":"Du","year":"2022","journal-title":"J Dermatolog Treat"},{"issue":"1","key":"10.1016\/j.jaad.2025.10.055_bib63","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jaci.2016.08.056","article-title":"IL-1 and IL-36 are dominant cytokines in generalized pustular psoriasis","volume":"140","author":"Johnston","year":"2017","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.jaad.2025.10.055_bib64","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/bjd.13614","article-title":"Treatment of two patients with generalized pustular psoriasis with the interleukin-1\u03b2 inhibitor gevokizumab","volume":"173","author":"Mansouri","year":"2015","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2025.10.055_bib65","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/j.jaad.2022.07.065","article-title":"Anakinra for refractory pustular psoriasis: a phase II, open-label, dose-escalation trial","volume":"87","author":"Naik","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2025.10.055_bib66","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/1346-8138.13622","article-title":"Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: results from a 52-week, open-label, phase 3 study (UNCOVER-J)","volume":"44","author":"Saeki","year":"2017","journal-title":"J Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962225030257?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962225030257?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T05:37:40Z","timestamp":1771393060000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962225030257"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":65,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S0190962225030257"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2025.10.055","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biologic therapies for dermatologic emergencies: A comprehensive review","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2025.10.055","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}